- Home
- MTEN vs AGEN Comparison
MTEN vs AGEN Comparison
Compare MTEN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEN
- AGEN
- Stock Information
- Founded
- MTEN 2015
- AGEN 1994
- Country
- MTEN China
- AGEN United States
- Employees
- MTEN N/A
- AGEN N/A
- Industry
- MTEN Building Products
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTEN Industrials
- AGEN Health Care
- Exchange
- MTEN Nasdaq
- AGEN Nasdaq
- Market Cap
- MTEN 36.9M
- AGEN 38.1M
- IPO Year
- MTEN 2024
- AGEN 2000
- Fundamental
- Price
- MTEN $4.22
- AGEN $2.08
- Analyst Decision
- MTEN
- AGEN Buy
- Analyst Count
- MTEN 0
- AGEN 4
- Target Price
- MTEN N/A
- AGEN $8.00
- AVG Volume (30 Days)
- MTEN 168.6K
- AGEN 439.0K
- Earning Date
- MTEN 05-21-2025
- AGEN 05-06-2025
- Dividend Yield
- MTEN N/A
- AGEN N/A
- EPS Growth
- MTEN N/A
- AGEN N/A
- EPS
- MTEN 0.13
- AGEN N/A
- Revenue
- MTEN $9,136,855.00
- AGEN $103,463,000.00
- Revenue This Year
- MTEN N/A
- AGEN $4.03
- Revenue Next Year
- MTEN N/A
- AGEN $5.57
- P/E Ratio
- MTEN $32.49
- AGEN N/A
- Revenue Growth
- MTEN 18.30
- AGEN N/A
- 52 Week Low
- MTEN $1.81
- AGEN $1.38
- 52 Week High
- MTEN $9.87
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- MTEN N/A
- AGEN 57.30
- Support Level
- MTEN N/A
- AGEN $1.60
- Resistance Level
- MTEN N/A
- AGEN $1.83
- Average True Range (ATR)
- MTEN 0.00
- AGEN 0.19
- MACD
- MTEN 0.00
- AGEN 0.08
- Stochastic Oscillator
- MTEN 0.00
- AGEN 94.59
About MTEN Mingteng International Corporation Inc. Ordinary Shares
Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides a wide range of products including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in automobile, construction machinery, and other manufacturing industries.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).